Elutia (NASDAQ:ELUT) versus Nano-X Imaging (NASDAQ:NNOX) Critical Analysis

Nano-X Imaging (NASDAQ:NNOX) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

21.5% of Nano-X Imaging shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Nano-X Imaging and Elutia, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nano-X Imaging	1	2	2	1	2.50
Elutia	1	0	0	0	1.00

Nano-X Imaging currently has a consensus price target of $4.33, suggesting a potential upside of 560.57%. Given Nano-X Imaging’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Nano-X Imaging is more favorable than Elutia.

Profitability

This table compares Nano-X Imaging and Elutia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nano-X Imaging	-926.05%	-116.93%	-100.67%
Elutia	426.93%	-407.37%	-47.08%

Risk & Volatility

Nano-X Imaging has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500.

Valuation and Earnings

This table compares Nano-X Imaging and Elutia”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nano-X Imaging	$15.63 million	3.30	-$75.02 million	($2.14)	-0.31
Elutia	$12.14 million	2.88	$53.38 million	$0.95	0.83

Elutia has lower revenue, but higher earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Summary

Nano-X Imaging beats Elutia on 8 of the 15 factors compared between the two stocks.

About Nano-X Imaging

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.

About Elutia

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.